NASDAQ : NTLA
Intellia Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 13.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.85B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.69B |
| Enterprise Value | 1.13B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 140.13M |
| Shares Outstanding | 140.13M |
| Shares Change (YoY) | +16.64% |
| Shares Change (QoQ) | +12.65% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 99.95% |
| Float | 134.21M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.36 |
| Forward PS | 32.41 |
| PB Ratio | 2.40 |
| P/TBV Ratio | 2.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 20.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.65 |
| Quick Ratio | 5.61 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -55.44% |
| Return on Assets (ROA) | -30.14% |
| Return on Invested Capital (ROIC) | -32.70% |
| Return on Capital Employed (ROCE) | -54.45% |
| Weighted Average Cost of Capital (WACC) | 13.58% |
| Revenue Per Employee | $157,841 |
| Profits Per Employee | -$1.06M |
| Employee Count | 377 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -1.74% |
| 50-Day Moving Average | 12.22 |
| 200-Day Moving Average | 13.08 |
| Relative Strength Index (RSI) | 52.74 |
| Average Volume (20 Days) | 5,247,493 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 44.44M |
| Short Previous Month | 45.11M |
| Short % of Shares Out | 31.71% |
| Short % of Float | 33.11% |
| Short Ratio (days to cover) | 7.63 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 59.51M |
| Gross Profit | -222.82M |
| Operating Income | -423.48M |
| Pretax Income | -399.98M |
| Net Income | -399.98M |
| EBITDA | -414.40M |
| EBIT | -423.48M |
| Loss Per Share | -$3.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 437.76M |
| Total Debt | 73.41M |
| Net Cash | 554.94M |
| Net Cash Per Share | $3.96 |
| Equity (Book Value) | 727.71M |
| Book Value Per Share | 5.20 |
| Working Capital | 448.44M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -346.64M |
| Capital Expenditures | -2.04M |
| Depreciation & Amortization | 9.08M |
| Net Borrowing | n/a |
| Free Cash Flow | -348.69M |
| FCF Per Share | -$2.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -711.66% |
| Pretax Margin | -672.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.64% |
| Shareholder Yield | -16.64% |
| Earnings Yield | -27.74% |
| FCF Yield | -19.95% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.11 |
| Price Target Difference | 91.71% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 76.44% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |